Evolving treatment paradigms for locally advanced and metastatic prostate cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 11, 2006, Pages 1639-1651

  Dorff, Tanya B ^a   Quek, Marcus L ^b   Daneshmand, Siamak ^c   Pinski, Jacek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Advanced; Advanced therapy; Chemotherapy; Immune therapy; Multimodality therapy; Prostate cancer; Targeted therapy

Indexed keywords

ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CANCER VACCINE; CAPECITABINE; CARBOPLATIN; CORTICOSTEROID; DN 101; DOCETAXEL; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; ESTROGEN; FLUOROURACIL; FLUTAMIDE; GEMCITABINE; GONADORELIN ANTAGONIST; GOSERELIN; HYDROCORTISONE; INTERLEUKIN 6 ANTIBODY; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO; PREDNISONE; SATRAPLATIN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ADVANCED CANCER; BIOLOGICAL THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; HEADACHE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PERIPHERAL EDEMA; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; RHINITIS; THROMBOSIS; TRANSURETHRAL RESECTION; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 33845349958     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.11.1639     Document Type: Review

References (87)

1. Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Kattan MW, Potters L, Blasko JC et al. A preoperative nomogram for for disease recurrence after radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 90, 766-771 (1998).
3. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millenium. Urology 58, 843-848 (2001).
4. D'Amico AV, Whittington R, Malkowicz SB et al. Pre-treatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 17, 168-172 (1999).
5. Johansson J, Holmberg J, Johansson S et al. Fifteen-year survival in prostate cancer. JAMA 277, 467-471 (1997).
6. Li R, Heydon K, Hammond ME et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy. An analysis of patients in RTOG 86-10. Clin. Cancer Res. 10, 4118-4124 (2004).
7. Chakravarti A, Heydon K, Wu CL et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the radiation therapy oncology group protocol 86-10. J. Clin. Oncol. 21, 3328-3334 (2003).
8. Bauer JJ, Sesterhenn IA, Mostofi FK, Mcleod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol. 156, 1511-1516 (1996).
9. Matsuhima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol. 158, 2278-2283 (1997).
10. Quek ML, Daneshmand S, Rodrigo S et al. Prognostic significance of neuroendocrine expression in lymphnode positive prostate cancer. Urology 67, 1247-1252 (2006).
11. Kattan MW, Shariat SF, Andrews B et al. The addition of interleukin-6 soluble receptor and transforming growth factor β1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol. 21, 3573-3579 (2003).
12. Hvamstad T, Jordal A, Hekmat N et al. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur. Urol. 44, 215-221 (2003).
13. Cohen MK, Arber DA, Coffield KS et al. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 74, 1899-1903 (1994).
14. George DJ, Halabi S, Shephard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9840. Clin. Cancer Res. 7, 1932-1936 (2001).
15. Levine AC, Liu X, Greengberg PD et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139, 4672-4678 (1998).
16. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomized trial. Lancet 360, 103-106 (2002).
17. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290 (2005).
18. Pilepich MV, Winter K, John MJ et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243-1252 (2001).
19. D'Amico AV, Manola J, Loffredo, M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAAV 292, 821-827 (2004).
20. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J. Clin. Oncol. 21, 3972-3978 (2003).
21. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int. J Radiat. Oncol. Biol. Phys. 59, 1352-1359 (2004).
22. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Br. J. Urol. Int. 95, 751-756 (2005).
23. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur. Urol. 32, 385-390 (1997).
24. Bastian PJ, Gonzalgo ML, Aronson WJ et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107, 1265-1272(2006).
25. Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JL. Radical prostatectomy for high grade disease: a reevaluation. J. Urol. 151, 1583 (1994).
26. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol. 152, 1843 (1994).
27. Oefelein MG, Smith ND, Grayhack JT, Schaeffer AJ, McVary KT. Long-term results of radical retropubic prostatectomy in men with high-grade carcinoma of the prostate. J. Urol. 158, 1460 (1997).
28. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5 year results. J. Urol. 167, 112-116 (2002).
29. Debruyne FM, Witjes WP. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol. Urol. 4, 251-256 (2000).
30. Klotz LH, Goldenberg SJ, Jewett MA et al. Long-term follow-up of a randomized trial of 0 vs 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 170, 791-794 (2003).
31. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 349, 906-910 (1997).
32. Tomlinson RL, Currie DP, Boyce WH. Radical prostatectomy: palliation for stage C carcinoma of the prostate. J. Urol. 117, 85-87 (1977).
33. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J. Urol. 168, 1008-1012 (2002).
34. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res. 11, 5233-5240 (2005).
35. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63, 1138-1142 (2004).
36. Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a Phase I/II study. J. Urol. 171, 709-713 (2004).
37. Gervasi LA, Mata J, Easly JD et al. Prognostic significance of lymph nodal metastases in prostate cancer. J. Urol. 142, 332-336 (1989).
38. Naya Y, Babaian RJ. Tbe predictors of pelvic lymph node metastasis at radical retropubic prostatectomy. J. Urol. 170, 2306-2310 (2002).
39. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J. Urol. 172(5 Pt 1). 1840-1844 (2004).
40. Burkhard FC, Bader P, Schneider E, Markwalder R, Studer UE. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur. Urol. 42(2), 84-90; discussion 90-92 (2002).
41. Schroder FH, Kurth KH, Fossa SD et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a Phase III study. J. Urol. 172(3), 923-927 (2004).
42. Swanson GP, Thompson IM, Basler J. Treatment options in lymph node-positive prostate cancer. Cancer 106, 2531-2539 (2006).
43. Aus G, Nordenskjold K, Robinson D, Rosell J, Varenhorst E. Prognostic factors and survival in node-posittve (N1) prostate cancer - a prospective study based on data from a Swedish population-based cohort. Eur. Urol. 43(6), 627-631 (2003).
44. Chavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J. Urol. 161, 1223-1227 (1999).
45. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 159, 357-364 (1998).
46. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1), 66-73 (2001).
47. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J. Urol. 169(3), 849-854 (2003).
48. Daneshmand S, Quek ML, Stein JP et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J. Urol. 172, 2252-2255 (2004).
49. Zwergel U, Lehmann J, Wullich B et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J. Urol. 171, 1128-1131 (2004).
50. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7, 472-479 (2006).
51. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am. 24(2), 395-406 (1997).
52. Frazier HA 2nd, Robertson JE, Paulson DF. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J. Urol. 12, 308-312 (1994).
53. Walsh PC. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. J. Urol. 164, 246-247 (2000).
54. Cadeddu JA, Partin AW, Epstein JI, Walsh PC. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 50, 251-255 (1997).
55. Grimm MO, Kamphausen S, Hugenschmidt H, Stephan-Odenthal M, Ackermann R, Vogeli TA. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur. Urol. 41, 628-634 (2002).
56. Kuefer R, Volkmer BG, Loeffler M et al. Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients. Prostate Cancer Prost. Dis. 7, 343-349 (2004).
57. Hanks GE, Buzydlowski J, Sause WT et al. Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int. J. Radiat. Oncol. Biol. Phys. 40, 765-768 (1998).
58. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial RTOG 85-31. J. Clin. Onc. 23, 800-807 (2005).
59. Schmid HP, Mihatsch MJ, Hering F, Rutishauser G. Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur. Urol. 31, 11-16 (1997).
60. Bhandari MS, Petryiak DP, Hussain M. Clinical trials in metastatic prostate cancer - has there been real progress in the past decade? Eur. J. Cancer 41, 941-953 (2005).
61. Kelly WM, Scher HI. Prostate specific antingen decline after antiandrogen withdrawl: the flutamide withdrawl syndrome. J. Urol. 149, 607 (1993).
62. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60(2), 201-208 (2002).
63. Byar DP. Proceedings of the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32, 1126-1130 (1973).
64. Medical Research Council Prostate Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the medical research council trial. Br. J. Urol. 79, 235-246 (1997).
65. Carroll PR, Kantoff PW, Balk SP et al. Overview Consensus Statement. Urology 60, 1-6 (2002).
66. Prostate Cancer Trialists Collaborativo Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 355, 1491-1498 (2000).
67. Calais Da Silva FM, Calais Da Silva F, Bono A et al. Phase III intermittent MAB vs continuous MAB. J. Clin. Oncol. 24, (2006) (Abstract 4513).
68. Hussain M, Tangen CM, Schellhammer PF et al. Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2). prostate cancer (PCa): data from Southwest Oncology Group trial 9346 (INT 0162). J. Clin. Onc. 24(S18), (2006) (Abstract 4517).
69. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawl alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a Phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025 (2004).
70. Hernes EH, Linja M, Fossa SD et al. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. Br. J. Urol. 86, 240-247 (2000).
71. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17, 2506 (1999).
72. Tannock IF, deWit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone. plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
73. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrune and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
74. Oh WK, Halabi S, Kelly WK et al. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98, 2592-2598 (2003).
75. Thakkar S, Hutson T, Garcia J et al. A Phase II trial of gemcitabine and docetaxel in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 24(S18), 14501 (2006).
76. Vasquez Estevez S, Mel Lorenzo J, Alvarez Gomez E, Quintero Aldana G. A Phase II study of biweekly docetaxel and vinorelbine for hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. 24(S18), 14529 (2006).
77. Marur S, Heilbrun L, Kucuk O et al. Phase II trial of weekly docetaxel and oral capecitabine in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 24(18S), 4634 (2006).
78. Hussain A, Dipaola RS, Baron AD et al. A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. 22(14S), (2004) (Abstract 4563).
79. Sternberg CN, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone refractory prostate cancer. Oncology 68, 2-9 (2005).
80. Hahn NM, Whalen C, Sweeney CJ. Second-line pemetrexed (P) for the treatment of hormone-refractory prostate cancer (HRPC): a Hoosier Oncology Group Phase II study - preliminary analysis. J. Clin. Oncol. 24 (2006) (Abstract 4644).
81. Droz JP, Muracciole X, Mottet N et al. Phase II study of oxaliplatin versus oxaliplatin combine with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Annals Oncol. 14, 1291-1298 (2003).
82. Vogelzang NJ, Nelson JB, Schulman CC et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone refractory prostate cancer. J. Clin. Oncol. 23(S16), (2005) (Abstract 4563).
83. Carducci M, Nelson JB, Saad F et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 22 (S14), (Abstract 4508) (2004).
84. Picus J, Halabi S. Rini B et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc. Am. Soc. Clin. Oncol. 22, (2003) (Abstract 1578).
85. Beer TM, Ryan CW, Venner PM et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus dooetaxel versus placebo plus docetaxel in androgen-independent prostate cancer (AIPC). J. Clin. Oncol. 23(S382), (2005) (Abstract 4516).
86. Venner PM, Ryan C, Petrylak DP et al. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. J. Clin. Oncol. 24(S18), 4505 (2006).
87. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006).